Lean NAFLD is associated with adverse liver events and mortality: Moving beyond BMI

被引：2
|
作者：
Do, Albert [1 ]
Lim, Joseph K. [1 ,2 ]
机构：
[1] Yale Sch Med, Yale Liver Ctr, Sect Digest Dis, New Haven, CT USA
[2] Yale Sch Med, Sect Digest Dis, POB 208019, New Haven, CT 06520 USA
来源：
HEPATOLOGY | 2023年 / 78卷 / 01期
关键词：
D O I：
10.1097/HEP.0000000000000360
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：6 / 7
页数：2
相关论文
共 50 条
  • [1] FACTORS ASSOCIATED WITH MORTALITY IN LEAN, OVERWEIGHT AND OBESE NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
    Golabi, Pegah
    Paik, James
    Arshad, Tamoore
    Afendy, Mariam
    Venkatesan, Chapy
    Younossi, Zobair M.
    HEPATOLOGY, 2019, 70 : 22A - 22A
  • [2] Liver-related mortality and morbidity of lean NAFLD is higher compared to overweight and obese NAFLD patients
    Feldman, A.
    Denkmayr, L.
    Strasser, M.
    Ruhaltinger, S.
    Strebinger, G.
    Huber-Schonauer, U.
    Niederseer, D.
    Stechemesser, L.
    Zandanell, S.
    Paulweber, B.
    Datz, C.
    Aigner, E.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S149 - S149
  • [3] Is the Risk of Mortality increased in Lean Patients in Non-alcoholic Fatty Liver Disease (NAFLD)?
    Younossi, Zobair M.
    Otgonsuren, Munkhzul
    Keo, Wisna'odom
    Gogoll, Trevor
    Arsalla, Aimal
    Badoe, Nina
    Ford, Joel S.
    Mann, Puneetinder
    Cooper, James N.
    Racila, Andrei
    HEPATOLOGY, 2016, 64 : 107A - 107A
  • [4] Non-alcoholic fatty liver disease (NAFLD) is associated with higher overall mortality and liver related mortality
    Ong, J. P.
    Pitts, A.
    Younossi, Z. M.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S5 - S5
  • [5] Nonalcoholic fatty liver disease (NAFLD): A new risk factor for adverse cardiovascular events in dialysis patients
    Mikolasevic, I.
    Racki, S.
    Zaputovic, L.
    Lukenda, V.
    Milic, S.
    Orlic, L.
    MEDICAL HYPOTHESES, 2014, 82 (02) : 205 - 208
  • [6] Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD
    Gawrieh, Samer
    Vilar-Gomez, Eduardo
    Wilson, Laura A.
    Pike, Francis
    Kleiner, David E.
    Neuschwander-Tetri, Brent A.
    Diehl, Anna Mae
    Dasarathy, Srinivasan
    Kowdley, Kris V.
    Hameed, Bilal
    Tonascia, James
    Loomba, Rohit
    Sanyal, Arun J.
    Chalasani, Naga
    JOURNAL OF HEPATOLOGY, 2024, 81 (04)
  • [7] ARE THERE DIFFERENT PREDICTORS OF MORTALITY IN LEAN AND OBESE/OVERWEIGHT PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)?
    Golabi, Pegah
    Otgonsuren, Munkhzul
    Tan, Daisong
    de Avila, Leyla
    Locklear, Cameron T.
    Fukui, Natsu
    Arsalla, Aimal
    Gogoll, Trevor
    Younossi, Zobair M.
    GASTROENTEROLOGY, 2017, 152 (05) : S684 - S684
  • [8] Fibrate-associated adverse effects beyond muscle and liver toxicity
    Florentin, M.
    Liberopoulos, E. N.
    Mikhailidis, D. P.
    Elisaf, M. S.
    CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (06) : 574 - 587
  • [9] Statin-associated adverse effects beyond muscle and liver toxicity
    Kiortsis, D. N.
    Filippatos, T. D.
    Mikhailidis, D. P.
    Elisaf, M. S.
    Liberopoulos, E. N.
    ATHEROSCLEROSIS, 2007, 195 (01) : 7 - 16
  • [10] Serum ferritin concentration predicts mortality and adverse liver events in patients with cirrhosis listed for liver transplantation
    Walker, N. M.
    Ryan, R. J.
    Fletcher, L. M.
    Nicol, J.
    Stuart, K. A.
    Crawford, D. H.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2008, 23 : A247 - A247
12345